CN105658795B - 免疫溶瘤疗法 - Google Patents

免疫溶瘤疗法 Download PDF

Info

Publication number
CN105658795B
CN105658795B CN201480058401.0A CN201480058401A CN105658795B CN 105658795 B CN105658795 B CN 105658795B CN 201480058401 A CN201480058401 A CN 201480058401A CN 105658795 B CN105658795 B CN 105658795B
Authority
CN
China
Prior art keywords
cancer
virus
trif
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480058401.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105658795A (zh
Inventor
S·H·瑟尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN105658795A publication Critical patent/CN105658795A/zh
Application granted granted Critical
Publication of CN105658795B publication Critical patent/CN105658795B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480058401.0A 2013-08-22 2014-08-22 免疫溶瘤疗法 Active CN105658795B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
US61/868,978 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (2)

Publication Number Publication Date
CN105658795A CN105658795A (zh) 2016-06-08
CN105658795B true CN105658795B (zh) 2020-07-03

Family

ID=52484194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480058401.0A Active CN105658795B (zh) 2013-08-22 2014-08-22 免疫溶瘤疗法

Country Status (28)

Country Link
US (2) US11478518B2 (cg-RX-API-DMAC10.html)
EP (3) EP3778897B1 (cg-RX-API-DMAC10.html)
JP (3) JP6912199B2 (cg-RX-API-DMAC10.html)
KR (1) KR102389240B1 (cg-RX-API-DMAC10.html)
CN (1) CN105658795B (cg-RX-API-DMAC10.html)
AU (1) AU2014308648B2 (cg-RX-API-DMAC10.html)
CA (3) CA3213715A1 (cg-RX-API-DMAC10.html)
CY (1) CY1126587T1 (cg-RX-API-DMAC10.html)
DK (2) DK3036329T3 (cg-RX-API-DMAC10.html)
EA (1) EA037582B1 (cg-RX-API-DMAC10.html)
ES (2) ES2847305T3 (cg-RX-API-DMAC10.html)
FI (1) FI3778897T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240078T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066593T2 (cg-RX-API-DMAC10.html)
IL (1) IL243996A0 (cg-RX-API-DMAC10.html)
LT (1) LT3778897T (cg-RX-API-DMAC10.html)
MD (2) MD4624C1 (cg-RX-API-DMAC10.html)
MX (1) MX2016002257A (cg-RX-API-DMAC10.html)
NZ (1) NZ716825A (cg-RX-API-DMAC10.html)
PE (1) PE20160673A1 (cg-RX-API-DMAC10.html)
PH (1) PH12016500329A1 (cg-RX-API-DMAC10.html)
PL (1) PL3778897T3 (cg-RX-API-DMAC10.html)
PT (1) PT3778897T (cg-RX-API-DMAC10.html)
RS (1) RS65104B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201600960PA (cg-RX-API-DMAC10.html)
SI (1) SI3778897T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400047T1 (cg-RX-API-DMAC10.html)
WO (1) WO2015027163A1 (cg-RX-API-DMAC10.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2847305T3 (es) 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
HK1255192A1 (zh) * 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP3432863A4 (en) * 2016-03-25 2019-11-13 University of Pittsburgh - of The Commonwealth System of Higher Education SYNTHETICALLY COVED VIRUS
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CA3070146A1 (en) * 2016-07-19 2018-01-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting stat3
JP2019528753A (ja) * 2016-09-21 2019-10-17 スティーブン エイチ． ソーン， 高移動度グループｂｏｘｉ突然変異体
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CA3052463A1 (en) * 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
US12566181B2 (en) 2017-03-06 2026-03-03 Immunofree, Inc. Methods and compositions for determining the potency of a therapeutic cellular composition
CN118892540A (zh) * 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
SG11202006457YA (en) * 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
CN112739374A (zh) * 2018-07-20 2021-04-30 安迅生物制药公司 唾液酸酶向癌细胞、免疫细胞和肿瘤微环境的递送
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113454231A (zh) * 2018-12-21 2021-09-28 渥太华医院研究所 修饰的正痘病毒载体
KR20210113632A (ko) * 2019-01-07 2021-09-16 칼리버 임뮤노쎄라퓨틱스, 인크. 암을 치료하는 방법
US11529402B2 (en) * 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP7326663B2 (ja) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
KR20220082025A (ko) * 2019-10-16 2022-06-16 칼리버 임뮤노쎄라퓨틱스, 인크. 변형된 세포외 외피보유 바이러스
CN114786715A (zh) * 2019-11-20 2022-07-22 匹兹堡大学联邦系统高等教育 痘苗病毒和使用痘苗病毒的方法
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
BR112022011158A2 (pt) * 2019-12-12 2022-08-30 Ignite Immunotherapy Inc Vírus vaccinia oncolítico variante e métodos de uso do mesmo
MX2022008547A (es) * 2020-01-09 2022-08-10 Pfizer Virus de vacuna recombinante.
KR20220152250A (ko) * 2020-03-06 2022-11-15 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스
CN116096906A (zh) * 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
US20240316104A1 (en) * 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
EP4551240A1 (en) * 2022-07-08 2025-05-14 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790310A (zh) * 2007-03-15 2010-07-28 杰能斯有限公司 溶瘤痘苗病毒癌症治疗
CN101912421A (zh) * 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
AU5446700A (en) 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
WO2007023725A1 (ja) * 2005-08-25 2007-03-01 Yokohama City University 遺伝子ワクチン
EP1933857A2 (en) 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20110038843A1 (en) * 2008-03-31 2011-02-17 Kusmartsev Sergei A Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
ES2847305T3 (es) 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912421A (zh) * 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
CN101790310A (zh) * 2007-03-15 2010-07-28 杰能斯有限公司 溶瘤痘苗病毒癌症治疗
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Biogenesis of vaccinia. Effects of inhibitors of glycosylation on virus-mediated activities";SUSAN WEINTRAUB et al.,;《VIROLOGY》;19770501;第78卷;第315页摘要部分 *
"CEA重组痘苗病毒对实验性CEA阳性肝癌的预防和治疗作用";李锦洲等;《郑州大学学报(医学版)》;20050731;第40卷(第4期);第667-669页 *
"Development of recombinant vesicular stomatitis virus for use as oncolytic vector";Delia Gutman et al.,;《Cytokine》;20111231;第56卷(第1期);第84页右栏第二段 *

Also Published As

Publication number Publication date
JP7333431B2 (ja) 2023-08-24
WO2015027163A1 (en) 2015-02-26
CY1126587T1 (el) 2026-02-25
CA3213683A1 (en) 2015-02-26
RS65104B1 (sr) 2024-02-29
PH12016500329A1 (en) 2016-05-02
PT3778897T (pt) 2024-02-01
EA201690444A1 (ru) 2016-08-31
JP2019205451A (ja) 2019-12-05
MD4624C1 (ro) 2019-10-31
SI3778897T1 (sl) 2024-03-29
EP3778897A1 (en) 2021-02-17
MD4624B1 (ro) 2019-03-31
JP6912199B2 (ja) 2021-08-04
US20230008089A1 (en) 2023-01-12
JP7021154B2 (ja) 2022-02-16
EP3036329A4 (en) 2017-08-02
AU2014308648A1 (en) 2016-03-03
EP4324918A2 (en) 2024-02-21
MD4748C1 (ro) 2021-09-30
HUE066593T2 (hu) 2024-08-28
CA2921041A1 (en) 2015-02-26
MX2016002257A (es) 2016-11-08
HK1223402A1 (zh) 2017-07-28
CA3213715A1 (en) 2015-02-26
ES2847305T3 (es) 2021-08-02
EP4324918A3 (en) 2024-04-24
FI3778897T3 (fi) 2024-01-25
SMT202400047T1 (it) 2024-03-13
MD4748B1 (ro) 2021-02-28
EA037582B1 (ru) 2021-04-16
KR102389240B1 (ko) 2022-04-20
DK3778897T3 (da) 2024-01-29
SG11201600960PA (en) 2016-03-30
HRP20240078T1 (hr) 2024-03-29
EP3036329A1 (en) 2016-06-29
JP2022062171A (ja) 2022-04-19
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
US20160235793A1 (en) 2016-08-18
AU2014308648B2 (en) 2020-11-12
PL3778897T3 (pl) 2024-04-02
US12514888B2 (en) 2026-01-06
EP3036329B1 (en) 2020-10-07
NZ716825A (en) 2022-02-25
LT3778897T (lt) 2024-02-12
WO2015027163A9 (en) 2016-04-14
IL243996A0 (en) 2016-04-21
JP2016527920A (ja) 2016-09-15
US11478518B2 (en) 2022-10-25
CN105658795A (zh) 2016-06-08
CA2921041C (en) 2023-10-31
EP3778897B1 (en) 2023-12-20
KR20160044529A (ko) 2016-04-25
PE20160673A1 (es) 2016-07-21
DK3036329T3 (da) 2021-01-11
ES2971528T3 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
US12514888B2 (en) Immuno-oncolytic therapies
AU2014308648A2 (en) Immuno-oncolytic therapies
US20250332208A1 (en) Oncolytic virus therapy
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
CN116162654A (zh) 用于癌症免疫疗法的重组痘病毒
CN107735103A (zh) 使用灭活的非复制型的修饰的痘苗病毒安卡拉（mva）作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
CA2982896A1 (en) Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
HK40104741A (en) Immuno-oncolytic therapies
HK40045119A (en) Immuno-oncolytic therapies
HK40045119B (en) Immuno-oncolytic therapies
HK1223402B (zh) 免疫溶瘤療法
HK40088792A (en) Recombinant poxviruses for cancer immunotherapy
JP2025538787A (ja) 抗腫瘍薬の調製におけるｄｒ－１８と腫瘍溶解性ワクシニアウイルスの使用
HK40119191A (en) Novel use of oncolytic virus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1223402

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant